Graves’ disease triggers an autoimmune attack on the tissues behind and around the eyes, causing them to swell, push the eyeballs forward, and restrict eye movement. Nearly half of people with Graves’ hyperthyroidism develop noticeable eye symptoms, ranging from mild dryness and irritation to, in 3 to 5% of cases, severe inflammation that threatens vision. The eye condition has its own name, thyroid eye disease (TED), and it follows a predictable pattern of flare and gradual burnout over months to years.
Why the Immune System Targets Your Eyes
In Graves’ disease, the immune system produces antibodies that mistakenly activate thyroid-stimulating hormone receptors. Those same receptors also sit on the surface of specialized cells called fibroblasts inside your eye sockets. When antibodies latch onto these receptors, they trigger the fibroblasts to multiply, produce a gel-like substance that absorbs water, and generate new fat tissue. The result is a growing mass of swollen, inflamed tissue packed into a bony space that can’t expand.
A second receptor on these fibroblasts, one normally involved in growth signaling, pairs up with the thyroid receptor to amplify the process. Together, the two receptors activate internal signaling chains that recruit immune cells (T cells, B cells, and macrophages) into the orbit and release chemical messengers that sustain inflammation. This is why the eye changes in Graves’ disease can progress even when thyroid hormone levels are well controlled: the immune attack on the orbital tissue is partly independent of thyroid function.
What It Feels Like
The earliest and most common symptoms are a dry, gritty sensation and a feeling of pressure behind the eyes. Many people notice their eyes look different before they feel anything wrong. Eyelids may appear puffy or retract upward, exposing more of the white of the eye and creating a wide-eyed or staring appearance. Sensitivity to light, excessive tearing, and redness are all common.
As the disease progresses, the swelling behind the eye pushes the eyeball forward, a change called proptosis. Normal eye protrusion measures roughly 15 to 18 mm depending on sex and ethnicity. In TED, one or both eyes may push several millimeters beyond those ranges. That forward shift can prevent the eyelids from closing completely, leaving the cornea exposed during sleep and accelerating dryness and irritation.
Double vision develops when the swollen muscles controlling eye movement lose their flexibility or become unevenly affected. You might notice it looking in one particular direction at first, then in more positions over time. Eye pain, especially when looking up or to the side, is another hallmark and reflects active inflammation in the muscles and surrounding fat.
The Timeline: Active Phase to Burnout
TED follows a well-documented pattern first described by Wilson Rundle. In the active or inflammatory phase, symptoms escalate over a period of 6 months to 5 years, with an average duration of about 2 years. During this window, swelling, redness, and pain are at their worst, and the disease is most responsive to anti-inflammatory treatment.
After the active phase peaks, the disease enters a plateau where inflammation persists but stops worsening. Eventually it reaches an inactive or “burnout” phase, typically around 18 months after symptoms begin. The inflammation fades, but the damage doesn’t fully reverse. Scarred, stiffened muscles and expanded fatty tissue remain, which is why some degree of bulging, lid retraction, or double vision often persists long-term even without ongoing inflammation. Smoking is the single biggest modifiable factor that extends the active phase and worsens outcomes.
Smoking and Other Risk Factors
Smokers with Graves’ disease face a dramatically higher risk of developing eye involvement. One large study found that smoking increased the odds of Graves’ eye disease nearly eightfold compared to nonsmokers. Among those who did develop eye problems, smokers had more severe disease regardless of how many cigarettes they smoked per day or how long they had smoked. Even light or occasional smoking carries significant risk. Quitting doesn’t instantly reverse the danger, but it removes the most powerful controllable driver of disease severity.
Radioactive iodine treatment for Graves’ hyperthyroidism can also worsen eye disease in some people, particularly those who already have active eye symptoms. Other risk factors include being female (though men who develop TED tend to have more severe forms), older age, and poorly controlled thyroid levels in either direction. Both uncontrolled hyperthyroidism and hypothyroidism from overtreatment can fuel orbital inflammation.
When Vision Is at Risk
The most serious complication is optic nerve compression, which occurs in 3 to 5% of people with Graves’ eye disease. When the muscles at the back of the eye socket swell enough to crowd the optic nerve where it exits the skull, the nerve’s blood supply and signal transmission are compromised. This condition is called dysthyroid optic neuropathy.
Warning signs include a noticeable drop in visual sharpness, colors appearing washed out or different between the two eyes, and blind spots in your field of vision. Doctors look for at least two of these indicators: declining visual acuity, impaired color vision, optic disc swelling visible on exam, visual field defects, or an abnormal pupil response where one pupil reacts less to light than the other. Optic neuropathy is a medical emergency that requires urgent treatment, as prolonged compression can cause permanent vision loss.
Corneal ulceration is the other serious threat. When the eyes protrude far enough that the lids can’t close, the cornea dries out and becomes vulnerable to breakdown and infection.
How Doctors Assess Severity
To determine whether TED is in an active, treatable phase, doctors use a scoring system called the Clinical Activity Score. It evaluates seven signs at initial assessment: spontaneous pain behind the eye, pain when trying to look around, redness of the eyelid, redness of the white of the eye, swelling of the small fleshy bump in the inner corner of the eye, swelling of the eyelids, and swelling of the clear membrane over the white of the eye. Each item scores one point, and a total of 3 or higher indicates active disease that may respond to anti-inflammatory treatment.
At follow-up visits, three additional measurements are added: increasing protrusion, decreasing eye movement range, and declining visual acuity, for a 10-point scale. This scoring guides treatment decisions, because therapies that target inflammation work best during the active phase and offer little benefit once the disease has burned out and left behind scar tissue.
Treatment Options
For mild disease, management focuses on comfort: lubricating eye drops, sunglasses for light sensitivity, and elevating the head during sleep to reduce morning puffiness. Selenium supplements have shown modest benefit in mild cases in European studies.
Moderate to severe active disease is treated with medications that suppress the immune-driven inflammation. Intravenous steroids given in a pulsed schedule over several weeks are a long-established first-line approach, sometimes combined with an immune-suppressing medication. The specific regimen varies by guidelines and individual circumstances.
A newer treatment that specifically blocks the growth factor receptor involved in orbital inflammation has shown striking results. In a pivotal clinical trial published in the New England Journal of Medicine, 78% of patients receiving this targeted therapy had a meaningful overall response, compared to just 7% on placebo. Eye protrusion decreased by an average of 2.82 mm (versus 0.54 mm with placebo), and 68% of patients with double vision saw improvement compared to 29% on placebo. This therapy works by interrupting the receptor partnership that drives fibroblast activation, directly addressing the root mechanism rather than broadly suppressing inflammation.
Once the disease reaches its inactive phase, residual changes like persistent protrusion, lid retraction, or double vision from scarred muscles can be addressed surgically. These procedures are typically staged: orbital decompression to reduce bulging first, then muscle surgery to correct alignment, and finally lid surgery to improve appearance and protect the cornea. Surgery is generally delayed until the disease has been stable for at least six months to avoid operating on tissues that are still changing.